| Literature DB >> 26341688 |
Xun Yuan1, Hua Wu1, Hanxiao Xu1, Huihua Xiong1, Qian Chu1, Shiying Yu1, Gen Sheng Wu2, Kongming Wu3.
Abstract
The Notch pathway is involved in cell proliferation, differentiation and survival. The Notch signaling pathway is one of the most commonly activated signaling pathways in cancer. Alterations include activating mutations and amplification of the Notch pathway, which play key roles in the progression of cancer. Accumulating evidence suggests that the pharmacological inhibition of this pathway can overcome chemoresistance. Efforts have been taken to develop Notch inhibitors as a single agent or in combination with clinically used chemotherapeutics to treat cancer. Some Notch inhibitors have been demonstrated to have therapeutic efficacy in preclinical studies. This review summarizes the recent studies and clinical evaluations of the Notch inhibitors in cancer.Entities:
Keywords: Clinical trials; Notch signaling; Targeted therapy; γ-Secretase inhibitor
Mesh:
Substances:
Year: 2015 PMID: 26341688 DOI: 10.1016/j.canlet.2015.07.048
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679